DelRicht Research is proud to highlight the outstanding performance of our dermatology teams in a recent Phase 2 clinical trial for hidradenitis suppurativa (HS), a chronic and often painful inflammatory skin condition that impacts quality of life for patients worldwide. Across our participating sites in Baton Rouge, LA, and Atlanta, GA, DelRicht achieved first site activation, first patient randomized, and 247% of our expected enrollment goal, demonstrating the precision, agility, and collaboration that define our embedded research model.

Delivering Excellence in a Complex Phase 2 Study

The sponsor’s enrollment plan targeted 204 participants across 72 sites in the United States. DelRicht was expected to enroll six participants across two sites, Louisiana Dermatology Associates (Dr. Ira Thorla) and Experience Dermatology (Dr. Zachary Eyre). By the end of the enrollment period, our teams had enrolled 14 qualified participants, ranking among the top enrollers in the study and establishing benchmarks in both start-up speed and data quality.

From the outset, the trial presented operational hurdles uncommon even in complex dermatology protocols. The introduction of a new pharmacodynamic (PD) sample-processing technique required use of a refrigerated centrifuge, a process unfamiliar to sites and essential for accurate biomarker collection. DelRicht’s teams collaborated closely with the vendor and study monitors to refine workflows, conduct targeted staff training, and ensure every sample was processed correctly and on schedule.

Operational Readiness that Sets the Pace

DelRicht’s success began with rapid activation. Dr. Zachary Eyre’s Atlanta team expedited regulatory document submission and start-up tasks to achieve activation just 44 days from award, a remarkable turnaround that set the pace for the entire study. Together with Dr. Ira Thorla’s Baton Rouge team, DelRicht became the first site network to reach activation and the first to randomize a patient nationwide. This achievement reflects the efficiency of our centralized start-up operations, which streamline regulatory submissions, contract execution, and site readiness to deliver faster study launches for sponsors and CROs.

The study’s narrow eligibility parameters, targeting adults aged 18-80 with clinically confirmed HS, required precise screening and strong physician oversight. Our embedded model enabled consistent communication between investigators and coordinators, allowing potential participants to be prequalified and educated quickly, resulting in fewer screen failures and accelerated enrollment momentum.

Collaboration, Precision, and Performance

The leadership of Dr. Ira Thorla and Dr. Zachary Eyre was instrumental in driving these results. Their deep clinical experience and patient-centered approach fostered trust and engagement within their practices, while DelRicht’s centralized operations provided the structure and oversight to maintain compliance and consistency across both sites.

This collaboration exemplifies how DelRicht’s embedded model transforms site performance, pairing the familiarity of community-based care with the rigor of coordinated research systems. The result: reliable execution, rapid readiness, and results that consistently exceed expectations.

Key Takeaways for Sponsors and CROs

First to Activate and First to Randomize, demonstrating unmatched start-up and operational agility.
247% of Enrollment Goal Achieved across two sites, highlighting the scalability of DelRicht’s embedded model.
Flawless PD Sample Processing, achieved through proactive vendor collaboration and staff training.
Dual-Site Leadership, with Dr. Thorla recognized as a Top Enroller studywide.

A Trusted Partner in Dermatology Research

DelRicht Research continues to deliver dependable, high-performance results across complex dermatology indications. From operational readiness to patient engagement, our approach ensures every partner gains both quality data and accelerated timelines.To learn more about partnering with DelRicht for your next dermatology or immunology program, visit www.DelRichtResearch.com or contact us to explore collaboration opportunities.